BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35930753)

  • 1. Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems.
    Yokoyama Y; Estok TM; Wild R
    Mol Cancer Ther; 2022 Oct; 21(10):1561-1572. PubMed ID: 35930753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
    Rais R; Lemberg KM; Tenora L; Arwood ML; Pal A; Alt J; Wu Y; Lam J; Aguilar JMH; Zhao L; Peters DE; Tallon C; Pandey R; Thomas AG; Dash RP; Seiwert T; Majer P; Leone RD; Powell JD; Slusher BS
    Sci Adv; 2022 Nov; 8(46):eabq5925. PubMed ID: 36383674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A redox-responsive prodrug for tumor-targeted glutamine restriction.
    Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
    J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.
    Moon D; Hauck JS; Jiang X; Quang H; Xu L; Zhang F; Gao X; Wild R; Everitt JI; Macias E; He Y; Huang J
    Prostate; 2024 Mar; 84(4):349-357. PubMed ID: 38084059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DON of Hope: Starving Pancreatic Cancer by Glutamine Antagonism.
    Pillai R; Papagiannakopoulous T
    Cancer Res; 2024 Feb; 84(3):349-350. PubMed ID: 38117482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of
    Novotná K; Tenora L; Prchalová E; Paule J; Alt J; Veeravalli V; Lam J; Wu Y; Šnajdr I; Gori S; Mettu VS; Tsukamoto T; Majer P; Slusher BS; Rais R
    J Med Chem; 2023 Nov; 66(22):15493-15510. PubMed ID: 37949450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism.
    Encarnación-Rosado J; Sohn ASW; Biancur DE; Lin EY; Osorio-Vasquez V; Rodrick T; González-Baerga D; Zhao E; Yokoyama Y; Simeone DM; Jones DR; Parker SJ; Wild R; Kimmelman AC
    Nat Cancer; 2024 Jan; 5(1):85-99. PubMed ID: 37814010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
    Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
    J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
    Lemberg KM; Vornov JJ; Rais R; Slusher BS
    Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor.
    Gao RD; Hin N; Prchalová E; Pal A; Lam J; Rais R; Slusher BS; Tsukamoto T
    Bioorg Med Chem Lett; 2021 Oct; 50():128321. PubMed ID: 34400301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
    Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
    Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma.
    Rais R; Jančařík A; Tenora L; Nedelcovych M; Alt J; Englert J; Rojas C; Le A; Elgogary A; Tan J; Monincová L; Pate K; Adams R; Ferraris D; Powell J; Majer P; Slusher BS
    J Med Chem; 2016 Sep; 59(18):8621-33. PubMed ID: 27560860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.
    Sharma NS; Gupta VK; Garrido VT; Hadad R; Durden BC; Kesh K; Giri B; Ferrantella A; Dudeja V; Saluja A; Banerjee S
    J Clin Invest; 2020 Jan; 130(1):451-465. PubMed ID: 31613799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Effects of Glutamine Inhibition Strategies on Antitumor CD8 T Cells.
    Madden MZ; Ye X; Chi C; Fisher EL; Wolf MM; Needle GA; Bader JE; Patterson AR; Reinfeld BI; Landis MD; Hathaway ES; Muka JE; O'Neil RT; Karijolich J; Philip M; Rathmell JC
    J Immunol; 2023 Aug; 211(4):563-575. PubMed ID: 37341499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Effects of Glutamine Antagonist 6-Diazo-5-Oxo-l-Norleucine in Mice with Alphavirus Encephalomyelitis.
    Manivannan S; Baxter VK; Schultz KL; Slusher BS; Griffin DE
    J Virol; 2016 Oct; 90(20):9251-62. PubMed ID: 27489275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive effects of inhibiting both mTOR and glutamine metabolism on the arthritis in SKG mice.
    Ueda Y; Saegusa J; Okano T; Sendo S; Yamada H; Nishimura K; Morinobu A
    Sci Rep; 2019 Apr; 9(1):6374. PubMed ID: 31011190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.
    Tenora L; Alt J; Dash RP; Gadiano AJ; Novotná K; Veeravalli V; Lam J; Kirkpatrick QR; Lemberg KM; Majer P; Rais R; Slusher BS
    J Med Chem; 2019 Apr; 62(7):3524-3538. PubMed ID: 30892035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.
    Leone RD; Zhao L; Englert JM; Sun IM; Oh MH; Sun IH; Arwood ML; Bettencourt IA; Patel CH; Wen J; Tam A; Blosser RL; Prchalova E; Alt J; Rais R; Slusher BS; Powell JD
    Science; 2019 Nov; 366(6468):1013-1021. PubMed ID: 31699883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-activated glutamine antagonist prodrug combined with combretastatin A4 nanoparticles for tumor-selective metabolic blockade.
    Zheng M; Xu H; Huang Y; Sun J; Zhang H; Lv Z; Liu Z; Tang Z; Chen X
    J Control Release; 2024 Jan; 365():480-490. PubMed ID: 38040341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.